NCCN clinical practice guidelines in oncology: prostate cancer early detection.
about
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsWhen prostate cancer remains undetectable: The dilemmaA national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer3-D photoacoustic and pulse echo imaging of prostate tumor progression in the mouse window chamber.Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/mlDAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisNomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study.Screening for prostate cancer: the debate continuesRelative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detectionCan urinary PCA3 supplement PSA in the early detection of prostate cancer?New serum biomarkers for prostate cancer diagnosis.Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center.Understanding preventive behaviors among mid-Western African-American men: a pilot qualitative study of prostate screeningHow should prostate specific antigen be interpreted?Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapyIdentification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.Biopsy follow-up of prostate-specific antigen tests.The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical ProstatectomyProspective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients.Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study.Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.Nomograms predicting long-term overall survival and cancer-specific survival in head and neck squamous cell carcinoma patientsRisk-based prostate cancer screening.Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review.Risk-based prostate cancer screening: who and how?The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study.A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men.Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screeningClinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.
P2860
Q24608493-614041F2-6558-4D25-8DD8-F87FBB704E22Q26795515-712D79B3-FDAB-44B7-A38C-582F6DE8FC41Q28652628-926D66AF-0278-42E1-B190-1E577871B206Q30470306-4AB4A7A7-6114-4BDA-A3F7-2EC1D24192A5Q31106048-FB442F37-BA88-4ACA-8908-F6A6F4AAE961Q33586771-D35B6E2B-2987-4A7D-A7B7-2ED43AD4B3A9Q33648534-5A970508-6202-47F1-A276-24A1D7DC67C4Q33885776-2A5F76E0-13B9-482E-AA54-493FA5FCEB83Q34084330-F9B1F63D-C05F-4CE0-BD68-D3D34366BCF7Q34326169-A8E126F4-D85A-45C8-BC62-43BB174DA42CQ34677200-293E67C6-DB4F-4DCB-92DD-6467FD59ED7BQ34692263-4FAB64F5-A890-4B65-9933-CCBB081F3C81Q34939111-16A449A7-B98E-4CC0-A7DC-52DAD96AE0D3Q35028222-6D367F89-2009-4CD1-A2DB-F58A6D07193FQ35087248-C66AF6CA-97B6-4D78-A476-45622BE40811Q35993964-60D7A35A-A4A7-4290-97BB-CC4ECA25C0C7Q36009824-EB4D9550-E625-46D1-8E71-7C83C7FB04F8Q36033729-7C6E7E87-9532-46B1-B675-8BD3919ACAF7Q36145417-73F91F8E-004C-440F-B5F9-071939947F62Q36267681-973328F4-709E-4340-AED0-81DF053B6B36Q36386904-821B9DFF-7C2E-4146-AF68-6518D1505C5FQ36416365-C478F381-40A7-4F79-B4EE-AB930B9D23E1Q36567436-D4DE613E-5636-4467-A5CE-937189BC8B68Q36831317-DA98C562-D5CF-493A-8E94-E3E44D2C8BBBQ36915269-242ECF90-B237-4885-881A-74E96BC87589Q37009160-41D2BFB6-9AF1-4B8F-AFEA-FD3B52FF1929Q37141849-434E3CC6-3FA1-407D-8A58-5A47827C95F4Q37179234-1F994BF3-065E-425F-A86C-5561299CC1A3Q37182853-61DA85CB-CF8A-421D-AF06-E93EFC06DF12Q37302853-C0B717DA-3740-446F-97AF-80584FF3C3D8Q37588238-4AC4AA6E-3A06-4687-85BC-1AD903465D4BQ37963657-8FE1FE46-E472-4C03-9CF1-8C77F3CE86D2Q37973351-D7F192F0-FF53-4B9E-8901-1C399BB7221BQ38093463-82DE69CB-66F3-4D63-9D58-4D0499C25363Q38684598-902F3967-27D7-4B54-AF57-325CA2573AF6Q39999913-839833A4-7164-470E-8DD2-DC40D362E476Q40123788-23D634D1-38D8-46DB-898E-E754ECAA5E43Q41350139-A9714F1C-DA0A-44CA-A847-29B0F4EDBC82Q41833638-0901B22A-DCD2-4A59-8B7B-C10F31F499B2Q47119316-6F448B2F-6384-4FBB-B3C2-4D1CCCB59736
P2860
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@ast
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@en
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@nl
type
label
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@ast
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@en
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@nl
prefLabel
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@ast
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@en
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@nl
P2093
P356
P1476
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
@en
P2093
Antoinette M Stroup
George P Hemstreet
H Ballentine Carter
Hans Lilja
J Erik Busby
James Mohler
John T Wei
Jonathan I Epstein
Joseph C Presti
P304
P356
10.6004/JNCCN.2010.0016
P577
2010-02-01T00:00:00Z